BioNexus Gene Lab Corp
BGLC- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001737523
No open-market purchases or sales by BioNexus Gene Lab Corp insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $27.2K in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding BioNexus Gene Lab Corp changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 3 | 4 | +1 |
| Shares | 65.7K | 130.3K | +64.6K (+98.3%) |
| Value | $30.3K | $58.2K | +$28.0K (+92.5%) |
New holders (3)
Institutions that held BioNexus Gene Lab Corp at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 83,308 | $37.1K | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 12,960 | $6.00K | 0.00% |
| Scientech Research LLC | 10,385 | $4.62K | 0.00% |
Sold out (2)
Institutions that held BioNexus Gene Lab Corp at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Virtu Financial LLC | 27,372 | $13.0K |
| HRT Financial LP | 14,672 | $6.00K |